Bunsen AI Co-Scientist: Schrödinger's New Drug Discovery Engine

The Four Core Functions

Bunsen's workflow centers on a closed-loop cycle:

1. Understand — Interprets the researcher's scientific objective in natural language.
2. Strategize — Develops a computational strategy, selecting the right physics-based methods for the problem.
3. Execute — Runs the molecular discovery workflow autonomously (docking, free-energy perturbation, ADME prediction, etc.).
4. Iterate — Analyzes results and refines the approach, closing the loop between AI reasoning and physics-based outcomes .

This design allows researchers to direct multi-step computational campaigns using natural language, with Bunsen handling the workflow automation and physics-based computation.

Key Competitors in the AI-for-Science Space

Google DeepMind — Co-Scientist

Co-Scientist is a multi-agent AI system built on Gemini 2.0, designed for structured hypothesis generation and scientific reasoning . Published in Nature in May 2026 , it uses seven specialized AI agents (Generation, Ranking, Evolution, Proximity, etc.) that debate and refine hypotheses. It has demonstrated the ability to propose novel therapeutic hypotheses — for example, drug repurposing for liver fibrosis — that were experimentally validated . The key difference from Bunsen is that Co-Scientist is a general biomedical hypothesis-generation engine; it does not natively integrate physics-based molecular simulation. It reads literature and generates ideas but relies on external tools or human researchers for computational chemistry execution .

FutureHouse — Robin

Robin is a multi-agent AI system for end-to-end biological discovery, also published in Nature in May 2026 . It automates the full cycle of hypothesis generation, experimental design, data analysis, and insight generation in one continuous workflow . Robin demonstrated its capabilities by autonomously identifying ripasudil (an existing glaucoma drug) as a promising therapy for dry age-related macular degeneration (dAMD) . It uses specialized sub-agents: Crow (literature Q&A), Falcon (deep synthesis), Owl (answering), and Phoenix (coding/analysis) . The key difference from Bunsen is that Robin is focused on experimental biology and drug repurposing, not computational chemistry, and lacks integrated physics-based molecular simulation engines .

Other Notable Competitors

Q1 2026 Financial Context

Schrödinger reported Q1 2026 results on May 5, 2026 with the following highlights:

• ACV (Annual Contract Value): $28.4 million in Q1, up 12% year-over-year; trailing four-quarter ACV was $201 million . Growth was driven by usage scale-ups with top-20 pharma customers and new product deployments .
• Total Revenue: $58.6 million, down 2% year-over-year (beating consensus by approximately 22%) .
• Software Revenue: $35.6 million, down 21% year-over-year, directly attributed to the accelerated shift from on-premise licenses to hosted (SaaS) delivery .
• Hosted Mix: Hosted software reached 34% of software revenue in Q1, up from 24% a year earlier . The company targets approximately 75% hosted by 2028 .
• Drug Discovery Revenue: $23 million, more than doubled (+124%) year-over-year .
• FY 2026 Guidance: Software ACV expected between $218–228 million (10–15% growth); drug discovery revenue between $55–65 million .

Management framed the hosted transition as a near-term headwind to recognized revenue but not to ACV or cash flow. Each 1% increase in hosted mix impacts reported revenue by roughly $2–3 million due to ASC 606 timing . The shift is intended to align revenue recognition with customer consumption and drive higher retention.

Cash Position

The available earnings summaries did not explicitly state a specific cash and equivalents figure for Q1 2026. However, Schrödinger has consistently maintained a strong balance sheet to fund ongoing platform development (including Bunsen) and its therapeutics pipeline. For precise Q1 2026 cash, cash equivalents, and marketable securities, the 10-Q filing would be the definitive source. In Q4 2025, Schrödinger reported robust liquidity, and management has expressed confidence that the hosted transition will not require additional capital .